Company

Bank

Analyst

Coverage

Opinion

Wk chg

11/30 cls

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

Needham

Alan Carr

Upgrade

Buy (from hold)

134%

$5.20

Carr also set a $9 target after Acadia reported that once-daily 40 mg oral pimavanserin as an adjunct to stable doses of existing anti-Parkinson's therapy met the primary endpoint in the Phase III ACP-103-020 trial to treat Parkinson's disease psychosis (PDP) (see B24). Acadia is planning an identical Phase III trial, but did not provide a timeline. Pimavanserin is a small molecule serotonin (5-HT2A) receptor inverse agonist.

Bruker Corp. (NASDAQ:BRKR)

Goldman Sachs

Isaac Ro

Upgrade

Buy (from neutral)

0%

$14.60

Ro raised his target to $19 from $13 on better-than-expected organic growth for the tool supply company. Bruker reported revenue of $447.8M and an EPS of $0.28 for 3Q12, beating the Street's estimates of $421.4M in revenue and an EPS of $0.15. Ro said the company is re-aligning its presence away from Europe into emerging markets, where long-term trends remain very favorable. He models 7% organic top-line growth for 2013-15 compared with about 5% for other tool companies. Bruker was up 7% for the week ended Nov. 23, when Ro issued his report.